Get the Stockscreener App
10.25
0.49%
0.05
After Hours:
10.24
-0.010
-0.10%
Neuropace Inc stock is traded at $10.25, with a volume of 60,915.
It is up +0.49% in the last 24 hours and up +61.42% over the past month.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.
See More
Previous Close:
$10.20
Open:
$10.2
24h Volume:
60,915
Relative Volume:
0.85
Market Cap:
$299.91M
Revenue:
$65.42M
Net Income/Loss:
$-32.96M
P/E Ratio:
-6.0294
EPS:
-1.7
Net Cash Flow:
$-19.87M
1W Performance:
+11.53%
1M Performance:
+61.42%
6M Performance:
+36.12%
1Y Performance:
+15.69%
1-Day Range:
$9.79
$10.46
1-Week Range:
$8.76
$10.77
52-Week Range:
$5.45
$18.15
Neuropace Inc Stock (NPCE) Company Profile
Name
Neuropace Inc
Sector
Industry
Phone
(650) 237-2700
Address
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Compare NPCE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
10.25 | 299.91M | 65.42M | -32.96M | -19.87M | -1.70 |
|
ABT
Abbott Laboratories
|
118.95 | 208.18B | 41.22B | 5.77B | 6.49B | 2.94 |
|
SYK
Stryker Corp
|
388.14 | 148.70B | 21.97B | 3.59B | 3.21B | 6.74 |
|
BSX
Boston Scientific Corp
|
90.75 | 133.32B | 15.91B | 1.79B | 1.89B | 0.82 |
|
MDT
Medtronic Plc
|
86.27 | 111.27B | 33.00B | 4.29B | 5.50B | 2.71 |
|
EW
Edwards Lifesciences Corp
|
72.07 | 42.66B | 6.60B | 4.16B | 490.10M | 2.34 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-14-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-30-24 | Initiated | Leerink Partners | Outperform |
| Nov-10-23 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-24-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-22-23 | Initiated | Lake Street | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-19-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-07-22 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-11-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-18-21 | Initiated | Robert W. Baird | Outperform |
| May-17-21 | Initiated | JP Morgan | Overweight |
| May-17-21 | Initiated | Morgan Stanley | Overweight |
| May-17-21 | Initiated | SVB Leerink | Outperform |
| May-17-21 | Initiated | Wells Fargo | Overweight |
View All
Neuropace Inc Stock (NPCE) Latest News
NeuroPace's SWOT analysis: epilepsy device maker's stock poised for growth - Investing.com
NeuroPace, Inc. (NASDAQ:NPCE) Receives $14.60 Average PT from Analysts - MarketBeat
NeuroPace, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Top 10 Deep Brain Stimulation Device Companies | Provides Best DevicesMarket.us Media - Market.us Media - United States Market News
NeuroPace (NASDAQ:NPCE) versus Cerus (NASDAQ:CERS) Financial Analysis - Defense World
NeuroPace, Inc. (NPCE) Reports Q3 Loss, Tops Revenue Estimates - MSN
What Makes NeuroPace (NPCE) a New Buy Stock - MSN
Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 54.34%: Here's is How to Trade - Yahoo Finance
NeuroPace FY2024 EPS Forecast Raised by Cantor Fitzgerald - Defense World
Cantor Fitzgerald Boosts Earnings Estimates for NeuroPace - MarketBeat
NeuroPace (NASDAQ:NPCE) Price Target Cut to $13.00 by Analysts at Wells Fargo & Company - Defense World
FY2024 EPS Estimates for NeuroPace Lifted by Leerink Partnrs - Defense World
NeuroPace FY2024 EPS Forecast Boosted by Leerink Partnrs - MarketBeat
NeuroPace Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Here's What Analysts Are Forecasting For NeuroPace, Inc. (NASDAQ:NPCE) After Its Third-Quarter Results - Simply Wall St
Long NPCE: NeuroPace Inc. Q3 Earnings, 28% Revenue Growth, Nautilus Study Progress, and Breakout from $6-$7 Consolidation Signal Bullish Momentum - Invezz
How the (NPCE) price action is used to our Advantage - Stock Traders Daily
NeuroPace price target lowered to $13 from $15 at Wells Fargo - TipRanks
NeuroPace, Inc. (NASDAQ:NPCE) Q3 2024 Earnings Call Transcript - Insider Monkey
500: Something went wrong - Investing.com Canada
NeuroPace Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance - The Manila Times
NeuroPace, Inc. Reports Strong Q3 2024 Results - TipRanks
NeuroPace Inc.: Q3 Earnings Snapshot - San Francisco Chronicle
Neuropace earnings beat by $0.08, revenue topped estimates - Investing.com UK
Neuroscience Market Projected to Reach USD 50.2 Billion by 2032, Growing at a 4.0% CAGR – S&S Insider - GlobeNewswire Inc.
Earnings To Watch: NeuroPace Inc (NPCE) Reports Q3 2024 Result - Yahoo Finance
NeuroPace (NPCE) Set to Announce Earnings on Tuesday - Defense World
private equity firms who own 45% along with institutions invested in NeuroPace, Inc. (NASDAQ:NPCE) saw increase in their holdings value last week - Yahoo Finance
Does NeuroPace (NASDAQ:NPCE) Have A Healthy Balance Sheet? - Simply Wall St
NeuroPace submits RNS System study data to FDA By Investing.com - Investing.com Australia
NeuroPace (NPCE) Set to Announce Quarterly Earnings on Tuesday - MarketBeat
NeuroPace Announces FDA Submission of Three-Year Data from Post-Approval Study of the RNS System in Focal Epilepsy - ForexTV.com
NeuroPace submits RNS System study data to FDA - Investing.com India
How to Take Advantage of moves in (NPCE) - Stock Traders Daily
Analysts Set NeuroPace, Inc. (NASDAQ:NPCE) Target Price at $14.00 - Defense World
NeuroPace, Inc. (NASDAQ:NPCE) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Strength Seen in NeuroPace (NPCE): Can Its 5.1% Jump Turn into More Strength? - MSN
Deep Brain Stimulation Devices Market Growing Popularity & Emerging Trends | Medtronic, NeuroPace, LivaNova - openPR
KCK LTD.'s Strategic Reduction in NeuroPace Inc Shares - Yahoo Finance
Neuropace shareholder KCK Ltd. sells $1.22 million in stock By Investing.com - Investing.com South Africa
Neuropace shareholder KCK Ltd. sells $1.22 million in stock - Investing.com
Ltd. Kck Sells 223,991 Shares of NeuroPace, Inc. (NASDAQ:NPCE) Stock - MarketBeat
KCK LTD. Adjusts Stake in NeuroPace Inc - GuruFocus.com
Neuropace Inc sees $24,853 stock sale by major shareholder - Investing.com
Page 85 – Impact Investing - Equities News
Neuropace stock hits 52-week low at $5.66 amid market challenges - Investing.com Australia
Neuropace Inc Stock (NPCE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Neuropace Inc Stock (NPCE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KCK LTD. | 10% Owner |
Oct 23 '24 |
Sale |
6.02 |
147 |
885 |
5,494,836 |
0.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):